Successful Treatment of Invasive Zygomycosis Based on a Prompt Diagnosis Using Molecular Methods in a Patient with Acute Myelogenous Leukemia

Junichiro Yuda¹, Koji Kato¹, Yoshikane Kikushige¹, Kiyofumi Ohkusu², Makiko Kiyosuke³, Keiji Sakamoto¹, Seido Oku¹, Noriko Miyake¹, Masako Kadowaki¹, Tadafumi Iino⁴, Kazuki Tanimoto¹, Katsuto Takenaka¹, Hiromi Iwasaki⁴, Toshihiro Miyamoto¹, Nobuyuki Shimono¹, Takanori Teshima¹ and Koichi Akashi¹

Abstract

Zygomycosis is a lethal and invasive mold infection that is often associated with hematological malignancies. The keys for successful treatment include making a rapid diagnosis and appropriately administering antifungal agents. We herein report the early diagnosis of a case of zygomycosis in a patient with acute myeloid leukemia using a deoxyribonucleic acid sequence analysis. We successfully performed allogeneic hematopoietic stem cell transplantation with the use of high-dose liposomal amphotericin B and granulocyte transfusion.

Key words: zygomycosis, liposomal amphotericin B, stem cell transplantation, polymerase chain reaction

[Intern Med 53: 1087-1091, 2014]

DOI: 10.2169/internalmedicine.53.1366

Introduction

Zygomycosis is an invasive mold infection caused by members of the order Mucorales that frequently occurs in patients with hematological malignancies (1). Zygomycosis can present as rhinocerebral, pulmonary or disseminated disease with a rapid clinical course and lethal outcome (2). In patients with neutropenia, mortality due to zygomycosis increases significantly if antimicrobial treatment is either inappropriate or delayed. Therefore, the key aspects to treat zygomycosis include making a rapid diagnosis and appropriately administering antifungal agents. However, making a diagnosis based on histology remains challenging, as zygomycosis is rare and the causative agent has a morphology resembling that of yeast-like or filamentous fungi. We herein report a case of disseminated *Rhizomucor pusillus* infection in a patient with acute myeloid leukemia (AML). Although it is difficult to diagnose zygomycosis based on the results of a histopathological examination only, conducting a deoxyribonucleic acid (DNA) sequence analysis can lead to a rapid diagnosis and appropriate treatment of *R. pusillus*.

Case Report

A 49-year-old man was referred to our hospital with general fatigue and a history of splenectomy for idiopathic thrombocytopenia. The patient’s white blood cell count was 3.3×10⁹/L, with 3% neutrophils and 6% myeloblasts, and he exhibited anemia (Hb, 6.9 g/dL) and thrombocytopenia (platelet count, 2.2×10⁹/L) (Table). Bone marrow aspiration revealed an increase in myeloblasts (up to 20%) with multilineage dysplasia, including a pseudo-Pelger-Huet anomaly in the myeloid lineage, megaloblastic changes in the erythroid lineage and the presence of micromegakaryocytes. The patient was diagnosed with AML with myelodysplasia.
related changes (MRC) based on the World Health Organization 2008 classification. A cytogenetic analysis showed a complex karyotype, including monosomy 7 (Fig. 1). The administration of combined chemotherapy with idarubicin and cytarabine was immediately started as induction therapy against AML. After the completion of the chemotherapy regimen, the patient’s neutropenia and fever continued despite the use of prophylactic antifungal treatment with fluconazole and broad-spectrum antibiotics. Cultures of blood, sputum, urine and stool were negative for fungi and bacteria, and the serum levels of galactomannan antigens and β-D-glucan were not elevated. However, on day 18 after the initiation of chemotherapy, the chest computed tomography (CT) findings showed a small nodular lesion in the upper right lobe of the lung. Treatment with intravenous voriconazole and broad-spectrum antibiotics. Cultures of blood, sputum, urine and stool were negative for fungi and bacteria, and the serum levels of galactomannan antigens and β-D-glucan were not elevated. However, on day 18 after the initiation of chemotherapy, the chest computed tomography (CT) findings showed a small nodular lesion in the upper right lobe of the lung. Treatment with intravenous voriconazole was initiated under a diagnosis of possible pulmonary aspergillosis infection based on the European Organization for Research and Treatment of Cancer/Invasive fungal infections cooperative group and National Institute of Allergy and Infectious Diseases Mycoses Study Group (10). The isolated fungus, according to a previously described method (4). Amplified PCR products of approximately 600 base pairs were sequenced and used to conduct a basic local alignment search of the GenBank sequence database (www.ncbi.nlm.nih.gov/blast/). The amplicon sequences were 100% identical to the corresponding sequences of the R. pusillus strain ATCC 46342 (GenBank accession number GU 256738). Based on the finding of invasive R. pusillus infection, treatment with intravenous liposomal amphotericin B (L-Amb) was initiated at a dose of 3 mg/kg, which was promptly increased up to 10 mg/kg, along with granulocyte colony-stimulating factor (G-CSF), which resulted in improvements in the patient’s symptoms, including the recovery of neutrophils (Fig. 4). The patient achieved hematological complete remission (CR) after receiving the induction therapy. Because CT scans continued to show abnormal findings, such as abscesses in the brain, liver and kidney, in addition to pneumonia, the L-Amb therapy was continued to treat disseminated zygomycosis. The severity of these symptoms made it a priority to treat the disseminated zygomycosis over the AML with MRC (Fig. 5A).

On day 96 after the initiation of the induction therapy, the percentage of leukemic myeloblasts in the bone marrow had increased to 15%. Despite the administration of low-dose cytarabine and aclacinon in order to decrease the leukemic burden, the patient failed to achieve CR, and cytogenetic markers indicating a poor prognosis were detected, suggesting the need for immediate allogeneic hematopoietic stem cell transplantation (allo-HSCT) to achieve a cure. Certainly, the risk of exacerbating the disseminated zygomycosis was extremely high. However, we performed allo-HSCT in addition to the administration of high-dose L-Amb (10 mg/kg). The reduced-intensity conditioning regimen consisted of fludarabine (Flu; 125 mg/m²) and intravenous busulfan (Bu; 12.8 mg/kg). Graft-versus-host disease prophylaxis consisted of cyclosporin A and mycophenolate mofetil. The CD34+ peripheral blood stem cells transplanted from a human leukocyte antigen-fully matched related donor (the patient’s elderly brother) were administered at a dose of 6.6×10⁶/kg. In addition, G-CSF-mobilized granulocytes were deliberately transfused from the same allo-HSCT donor on days 2 and 3 and from the patient’s son on days 2 and 9 after allo-HSCT. Engraftment of neutrophils was observed on day 12 after allo-HSCT (Fig. 4), and the disseminated zygomycosis was not exacerbated during the neutropenic period of allo-HSCT (Fig. 5B).

Discussion

Zygomycosis is a lethal opportunistic fungal complication observed in immunocompromised patients, particularly those with hematological malignancies, for which therapeutic options are limited. In patients with only localized infection, performing surgical excision and debridement is fundamental for a chance of cure. However, over the past decade, several new antifungal drugs suitable for clinical use and novel strategies for treating invasive fungal infection have been developed (5). Posaconazole and L-Amb are currently available and exhibit good activity against zygomycosis (2, 6), although voriconazole is not effective, as shown in the pre-

### Table. Laboratory Findings on Admission

<table>
<thead>
<tr>
<th>RBC (×10⁹/μL)</th>
<th>TP (g/dL)</th>
<th>Hb (g/dL)</th>
<th>ALB (g/dL)</th>
<th>Plt (×10⁹/μL)</th>
<th>T-Bil (mg/dL)</th>
<th>WBC (×10⁹/μL)</th>
<th>AST (U/L)</th>
<th>Neut (×10⁹/μL)</th>
<th>ALT (U/L)</th>
<th>Lymph (%)</th>
<th>Baso (%)</th>
<th>Eosino (%)</th>
<th>N-myelo (%)</th>
<th>Blast (%)</th>
<th>PT-TIME (sec)</th>
<th>PT-INR</th>
<th>APTT (sec)</th>
<th>Fibrinogen (mg/dL)</th>
<th>FDP (µg/mL)</th>
<th>D-dimer (µg/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>188 ± 10¹</td>
<td>7.5</td>
<td>6.9</td>
<td>4.3</td>
<td>2.2 ± 10¹</td>
<td>0.3</td>
<td>3230</td>
<td>11</td>
<td>4.0</td>
<td>10</td>
<td>85.5</td>
<td>1.0</td>
<td>2.5</td>
<td>1.0</td>
<td>6.0</td>
<td>10.8</td>
<td>1.01</td>
<td>31.8</td>
<td>357</td>
<td>0.2</td>
<td>0.7</td>
</tr>
</tbody>
</table>
**Figure 1.** Bone marrow aspirates showing hypocellular marrow with myeloblasts (A) and multilinage dysplasia (B) (Wright-Giemsa stain, ×1,000). Giemsa-banded karyogram of the bone marrow cells, as follows: 45, XY, dic(3;18)(p13;p11.2), der(5;17)(p10;q10), -7, dic(13;15)(p11.2;q11.2), add(19)(p11), +21, idic(22)(p11.2).

**Figure 2.** (A) High-resolution chest computed tomography revealed ground-glass opacity around a consolidated area in the right lobe. (B) T2-weighted magnetic resonance imaging demonstrated cerebral infarction in the left occipital lobe.

**Figure 3.** (A) Colonies formed from the pleural effusion fluid cultured on Sabouraud agar at 37°C for three days. (B) Photomicrograph of lactophenol cotton blue-stained fungi.
sent case. Because posaconazole has not yet been approved for use in Japan, L-AmB was the only choice of treatment in this case. L-AmB is available with less nephrotoxicity than conventional AmB; therefore, L-AmB can be administered safely at much higher doses (10 mg/kg), even in the setting of allo-HSCT. In addition, the transfusion of granulocytes likely decreases the risk of exacerbated invasive zygomycosis during the period of neutropenia that occurs after allo-HSCT (7, 8). Nevertheless, unlike invasive aspergillosis, zygomycosis is extremely rare, and the outcome of invasive zygomycosis treatment remains disappointing due to its association with a high mortality rate in immunocompromised patients (9).

In the present case, combined treatment consisting of the
transfusion of high-dose L-AmB (2) and granulocytes (8) may account for the positive treatment outcome. However, the primary key to the successful treatment of disseminated zygomycosis was the rapid diagnosis of *R. pusillus* using the PCR method (10), which enabled the patient to undergo allo-HSCT in association with directed treatment comprising high-dose L-AmB, improving the prognosis and chance of survival (11). In general, diagnosing zygomycosis is more difficult than other fungal infections, as there are no specific clinical signs or biomarkers for identifying this fungal species (5). The serum levels of Aspergillus GM antigens or β-D-glucan are usually not elevated in patients with invasive zygomycosis. Therefore, conducting an early examination upon the suspicion of zygomycosis is very important, and tissue biopsies, the gold standard for diagnosis, should be performed in order to document zygomycosis when possible. Nevertheless, the rate of positive fungal cultures is usually low (12), and it is difficult to morphologically classify fungi to the species level. In this case, *R. pusillus* was detected in the pleural effusion, which is usually sterile, using PCR. We believe that PCR-based methods are useful for promptly confirming the classification of zygomycosis at the species level (13). In order to appropriately select antifungal agents, differentiating zygomycosis from more common opportunistic molds, such as Aspergillus, is also very important. Voriconazole, which is used as a first-line treatment for invasive pulmonary aspergillosis, does not exhibit good activity against zygomycosis (3). *Cunninghamhamella* species, which can cause zygomycosis with an aggressive clinical course, must be treated with high-dose L-AmB (14). Because molecular techniques are not widely clinically validated, they should be used to make a definitive diagnosis with caution in combination with morphological methods.

In conclusion, the correct identification and early diagnosis of invasive zygomycosis is necessary to initiate timely and appropriate antifungal therapy, as invasive zygomycosis can have a fatal outcome. The PCR method is useful for obtaining the appropriate diagnosis; however, further validation is required before this method can be routinely used in the clinical setting.

The authors state that they have no Conflict of Interest (COI).

References


© 2014 The Japanese Society of Internal Medicine
http://www.naika.or.jp/imonline/index.html